CRI 2021 : Macrodosing, Microdosing and Ketamine Assisted Psychotherapy

Full title of the webinar: Macrodosing, Microdosing and Ketamine Assisted Psychotherapy: Tracking New Developments in the Psychedelic Renaissances Speaker : Zachary Walsh Moderator : Joël Tremblay This webinar was part of the annual seminar Convergence Research Intervention (CRI) co-organized by the RISQ, the IUD, the HERMES team, the AQCID, and the AIDQ held on June 3rd, 2021. More informations: https://bit.ly/3uK7udi Summary: The past decade has witnessed a dramatic increase in interest in the therapeutic application of psychedelic medicines including “classic” 5HT2A receptor agonists such as psilocybin and LSD, and associated medicines such as ketamine. This presentation will focus on research from our group examining mechanisms that might underly the actions of large (macro) doses of classic psychedelics and implications for psychedelic psychotherapy. We will also examine new findings regarding the use of smaller (micro) doses of psychedelics for improving mental health and well- being. Finally we will explore the use of ketamine in mental health and the potential role of ketamine-assisted psychotherapy in the broader psychedelic landscape.